NCT02976467 (CHIARA MIA 2) is a Phase 2 clinical trial of Fulacimstat (BAY1142524) in Myocardial Infarction, sponsored by Bayer.

Who is sponsoring NCT02976467?

NCT02976467 is sponsored by Bayer.

What drugs are being tested in NCT02976467?

Interventions in NCT02976467: Fulacimstat (BAY1142524), Placebo.

What condition does NCT02976467 study?

NCT02976467 studies Myocardial Infarction.

Is NCT02976467 still recruiting?

NCT02976467 is currently completed. Last updated 3 September 2019.

Last reviewed 2019-09-03 · How we verify

NCT02976467: CHIARA MIA 2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY 1142524 in Patients After Acute Myocardial Infarction With Left-ventricular Dysfunction

Completed Phase 2 Last updated 3 September 2019

What this trial tests

Phase 2 trial testing Fulacimstat (BAY1142524) in Myocardial Infarction in 107 participants. Completed in 4 September 2018.

Timeline

30 December 2016

Primary endpoint
31 July 2018

4 September 2018

Quick facts

Lead sponsor	Bayer
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	107
Start date	30 December 2016
Primary completion	31 July 2018
Estimated completion	4 September 2018
Sites	25 locations across Italy, Israel, Germany, Spain, Czechia

Drugs / interventions tested

Fulacimstat (BAY1142524) — full drug profile →
Placebo

Conditions studied

Myocardial Infarction — all drugs for Myocardial Infarction →

Sponsor

Bayer — full company profile →

Who can join

Adults 40 to 79, any sex, with Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the trial is the analysis of safety and efficacy of the chymase inhibitor BAY1142524 at a dose of 25 mg BID in comparison to placebo using a 6 months treatment period in patients with left-ventricular (LV) dysfunction after myocardial infarction (MI). BAY1142524 or placebo will be given on top of evidence-based standard of care for left-ventricular dysfunction after myocardial infarction. Primary objective is the analysis of first signs of efficacy as determined by favourable changes in functional parameters of adverse cardiac remodelling (i.e. endsystolic and enddiastolic volume index, ejection fraction). Secondary objective is the analysis of safety and tolerability as evidenced by the incidence and severity of adverse events. 30 patients have to complete treatment with verum and 30 patients have to complete treatment with placebo.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

A novel hamster nonalcoholic steatohepatitis model induced by a high-fat and high-cholesterol diet.
Miyaoka Y, Jin D, Tashiro K, Masubuchi S, et al · · 2018 · cited 10× · PMID 29311502 · DOI 10.1538/expanim.17-0126
A Chymase Inhibitory RNA Aptamer Improves Cardiac Function and Survival after Myocardial Infarction.
Jin D, Takai S, Nonaka Y, Yamazaki S, et al · · 2019 · cited 9× · PMID 30572223 · DOI 10.1016/j.omtn.2018.11.001

Verify or expand the search:

Other trials of Fulacimstat (BAY1142524)

Trials testing the same drug.

NCT03402438 — Renal Impairment Study · Phase 1 · completed
NCT03412006 — A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY1142524 in Patients With Type II Diabetes an · Phase 2 · completed

Other recruiting trials for Myocardial Infarction

Currently open trials in the same condition.

NCT07257198 — Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone · Phase 3 · recruiting
NCT07402642 — Effect of Early Educational Intervention on Cardiovascular Risk Factors After Acute Coronary Syndrome · NA · recruiting
NCT07301034 — A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, · Phase 3 · recruiting
NCT07142265 — Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients · recruiting
NCT07138911 — Effect of Home-based Exercise Plan Mediated by Use of Digital Health App on Kinesiophobia and Functional Capacity · NA · recruiting

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02976467 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 3 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02976467.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing